We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts, Elligo Health Enter in Strategic Partnership
Read MoreHide Full Article
Renowned information technology and service provider to healthcare organizations, Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) , announced that it has entered into a strategic partnership with Elligo Health Research.
Per the agreement, the companies would focus on assisting clinicians to conduct clinical trial studies in their own clinics. Through the aforementioned partnership, clinical trials managed by Clinical Research Organizations (CROs) will be helped by bringing new treatments to patients across major therapeutic areas.
The combined offering enables physicians to directly participate as study investigators in selected CRO clinical trials, which will provide patients with the benefit of more direct comprehensive care. Additionally, physicians will be able to generate research revenue and cover investigator fees associated with trial procedures. The Allscripts’ proprietary eParticipate service will be available to all the CROs – Allscripts Professional EHR, Allscripts TouchWorks EHR and Allscripts Sunrise.
CROs market is becoming more and more lucrative. Per a company estimate, they continue to increase investments to support bringing new clinical therapies to market, with more than $17 billion in payments to study investigators. eParticipate expands the reach of clinical trials investments by enabling Allscripts’ research-capable sites to become study investigators through Elligo Health’s infrastructure and services. Allscripts physicians will have access to clinical trials across several therapeutic areas, including Gastroenterology, Neurology, Pain, Urology, Pulmonology, Oncology and Women’s Health, some of the key areas of focus for CROs.
Over the past one month, Allscripts has outperformed the broader industry. The stock has gained 7.3%, compared with the 2.4% loss of the industry it belongs to.
Allscripts is a leading provider of healthcare information technology solutions. Looking forward, management is focused on various restructuring initiatives such as streamlining operational efficiency, increasing R&D and catering to client needs. We believe favorable demographic trends, reinforced by a supportive regulatory environment, are expected to sustain growth in demand for its services.
Higher client demand for the company’s population health management solutions by healthcare systems, hospitals and ambulatory markets should also drive growth over the long haul.
Zacks Rank & Key Picks
Allscripts Healthcare currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 3.2% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 29.6% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
Image: Bigstock
Allscripts, Elligo Health Enter in Strategic Partnership
Renowned information technology and service provider to healthcare organizations, Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) , announced that it has entered into a strategic partnership with Elligo Health Research.
Per the agreement, the companies would focus on assisting clinicians to conduct clinical trial studies in their own clinics. Through the aforementioned partnership, clinical trials managed by Clinical Research Organizations (CROs) will be helped by bringing new treatments to patients across major therapeutic areas.
The combined offering enables physicians to directly participate as study investigators in selected CRO clinical trials, which will provide patients with the benefit of more direct comprehensive care. Additionally, physicians will be able to generate research revenue and cover investigator fees associated with trial procedures. The Allscripts’ proprietary eParticipate service will be available to all the CROs – Allscripts Professional EHR, Allscripts TouchWorks EHR and Allscripts Sunrise.
CROs market is becoming more and more lucrative. Per a company estimate, they continue to increase investments to support bringing new clinical therapies to market, with more than $17 billion in payments to study investigators. eParticipate expands the reach of clinical trials investments by enabling Allscripts’ research-capable sites to become study investigators through Elligo Health’s infrastructure and services. Allscripts physicians will have access to clinical trials across several therapeutic areas, including Gastroenterology, Neurology, Pain, Urology, Pulmonology, Oncology and Women’s Health, some of the key areas of focus for CROs.
Over the past one month, Allscripts has outperformed the broader industry. The stock has gained 7.3%, compared with the 2.4% loss of the industry it belongs to.
Allscripts is a leading provider of healthcare information technology solutions. Looking forward, management is focused on various restructuring initiatives such as streamlining operational efficiency, increasing R&D and catering to client needs. We believe favorable demographic trends, reinforced by a supportive regulatory environment, are expected to sustain growth in demand for its services.
Higher client demand for the company’s population health management solutions by healthcare systems, hospitals and ambulatory markets should also drive growth over the long haul.
Zacks Rank & Key Picks
Allscripts Healthcare currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 3.2% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 29.6% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
See Stocks Now>>